<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113943</url>
  </required_header>
  <id_info>
    <org_study_id>C13-03</org_study_id>
    <secondary_id>2013-003496-35</secondary_id>
    <nct_id>NCT02113943</nct_id>
  </id_info>
  <brief_title>Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation</brief_title>
  <acronym>MBBCitalopram</acronym>
  <official_title>Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du Citalopram Sur Les paramètres Cognitifs de la Motivation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to examine the role of serotonin on the cognitive parameters
      of motivation. They are embedded in a conceptual framework of motivation that merges
      decision-making and reinforcement learning theories. Every action is conceived as path from
      one state to another. The different states are associated to different values (positive for
      rewards and negative for punishments), and the different actions to different costs (risk,
      effort and delay). The tasks are designed such that the sensitivity to the state and action
      parameters can be inferred by fitting computational models.The primary objective is to
      characterize the effect of Citalopram 30mg on reward sensitivity, assessed in an incentive
      force task, in which participants are asked to squeeze a hand grip to win monetary rewards.
      Secondary objectives are to characterize the effect of Citalopram 30mg on other cognitive
      parameters of motivation (assessed with a motivational battery that includes rating, choice
      and learning tasks).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>Reward sensitivity</measure>
    <time_frame>Multiple Time Frame: 2h after placebo, 2h after Citalopram 30mg</time_frame>
    <safety_issue>No</safety_issue>
    <description>Apathy will be assessed as the sensitivity to rewards in an incentive force task.
The primary Outcome measure is the change in this parameter between the placebo condition and the Citalopram condition.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment>24</enrollment>
  <condition>Normal Volunteers</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram 30mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman, age ≥ 18 and &lt; 50

          -  Weight between 50 kg and 90 kg.

          -  No contraindication to effort

          -  No evolutive pathology that could interfere with the current study signed consent

          -  medical insurance (&quot;sécurité sociale&quot;)

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 50

          -  Smokers

          -  Person under curatorship, or guardianship, or with civil rights deprivation

          -  History of neurologic or psychiatric pathology

          -  Presence of any psychotropic treatment

          -  Chronic or actual consumption of alcohol, or psychotropic drugs

          -  pregnancy, breastfeeding

          -  Woman of childbearing potential without effective contraception

          -  Hypersensitivity to atomoxetine or other constituents of the product

          -  Pheochromocytoma

          -  Narrow angle Glaucoma

          -  Liver failure

          -  Severe Cardiovascular Disorders

          -  Severe Cerebrovascular Discorders

          -  Treatment with non-selective Monoamine Oxidase Inhibitor (MAOI) : iproniazide.

          -  Treatment with Linezoline, Lithium, Milleperthuis, Tramadol, tryptans.

          -  Treatment with Pimozide, or treatment that can induce a QT prolongation
             (neuroleptics, class IA and III antiarrythmic, moxifloxacine, erythromicine,
             methadone, mefloquine, tricyclic antidepressants, lithium, cisapride), or treatment
             that can induce an hydroelectrolytic inbalance (thiazide diuretics).

          -  Treatment with Anticoagulants

          -  Treatment that can decrease seizure threshold: antidepressants, neuroleptics,
             mefloquine, buproprione, tramadol

          -  Enzyme inducers, (rifampicine, …)

          -  Treatment that can interfere with the performance of the subject: beta2 adrenergic
             agonists, analgesics, corticosteroïds, anti-inflammatory drugs, …
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Christophe Corvol, MCU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC Neurologie GH Pitié Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC Neurologie GHPS</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean Christophe Corvol, MCU-PH</last_name>
      <phone>0157274658</phone>
      <email>jccorvol@icm-institute.org</email>
    </contact>
    <contact_backup>
      <last_name>Mathias Pessiglione, PhD</last_name>
      <phone>0157274324</phone>
      <email>mathias.pessiglione@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 11, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
